Matthew Winkler
Direktor/Vorstandsmitglied bei AKOYA BIOSCIENCES, INC.
Vermögen: 4 Mio $ am 30.04.2024
Profil
Dr. Matthew M.
Winkler is an Independent Director at Akoya Biosciences, Inc. He is on the Board of Directors at Akoya Biosciences, Inc., Genetic Literacy Project, Revive & Restore and The Breakthrough Institute.
Dr. Winkler was previously employed as an Independent Director by Mirna Therapeutics, Inc., a Chairman by Asuragen, Inc., a Chief Executive Officer by Ambion, Inc., and an Associate Professor by The University of Texas at Austin.
He also served on the board at Second Genome, Inc. He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AKOYA BIOSCIENCES INC
1,99% | 31.03.2024 | 984 513 ( 1,99% ) | 4 Mio $ | 30.04.2024 |
Aktive Positionen von Matthew Winkler
| Unternehmen | Position | Beginn |
|---|---|---|
| AKOYA BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 01.07.2017 |
| The Breakthrough Institute | Direktor/Vorstandsmitglied | 01.01.2017 |
| Revive & Restore | Direktor/Vorstandsmitglied | 01.01.2017 |
| Genetic Literacy Project | Direktor/Vorstandsmitglied | 01.01.2017 |
Ehemalige bekannte Positionen von Matthew Winkler
| Unternehmen | Position | Ende |
|---|---|---|
Ambion, Inc.
 Ambion, Inc. Pharmaceuticals: MajorHealth Technology Ambion, Inc. develops and supplies RNA based life science research and molecular biology products. It specializes in the development of products for stabilizing, synthesizing, handling, isolating, storing, detecting and measuring RNA. The company was founded in November 1988 and is headquartered in Austin, TX | Vorstandsvorsitzender | 01.03.2016 |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Direktor/Vorstandsmitglied | 01.03.2016 |
| The University of Texas at Austin | Corporate Officer/Principal | 01.01.1991 |
Mirna Therapeutics, Inc.
 Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Gründer | - |
Asuragen, Inc.
 Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Gründer | - |
Ausbildung von Matthew Winkler
| University of California, Berkeley | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AKOYA BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Ambion, Inc.
Ambion, Inc. Pharmaceuticals: MajorHealth Technology Ambion, Inc. develops and supplies RNA based life science research and molecular biology products. It specializes in the development of products for stabilizing, synthesizing, handling, isolating, storing, detecting and measuring RNA. The company was founded in November 1988 and is headquartered in Austin, TX | Health Technology |
Asuragen, Inc.
Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Health Technology |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Health Technology |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Commercial Services |
| The Breakthrough Institute | |
| Revive & Restore | |
| Genetic Literacy Project |
